Preservation of Beta Cell Function in Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Trial Profile

Preservation of Beta Cell Function in Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Dapagliflozin (Primary) ; Metformin (Primary) ; Pioglitazone (Primary) ; Saxagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2020.
    • 07 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2020.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top